ReviewAntibiotics (Basel, Switzerland)2023
Liposomes-Based Drug Delivery Systems of Anti-Biofilm Agents to Combat Bacterial Biofilm Formation.
Review in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Addition of Selenium to Silver Nanoparticles: An Approach to Enhance Their Antimicrobial and Biological Properties - Systematic Review.Biological trace element research · 2026Pooled it
- Biofilm-mediated antibiotic tolerance in bacterial pathogens: Integrated molecular networks and novel therapeutic avenues.Virulence · 2026Review
- Biomimetic Coacervate Coatings: From Phase Separation Fundamentals to Advanced Biomedical Applications.Biomimetics (Basel, Switzerland) · 2026Review
- Nano-warfare in the oral cavity: antimicrobial strategies and mechanisms in nanodentistry.Odontology · 2026Review
- Curcumin Nanoencapsulated in Chitosan-Coated Liposomes: Therapeutic Potential against PathogenicACS omega · 2026Article
- Nanoparticle carriers in the treatment of intracellular bacterial infections: Current approaches and challenges.International journal of pharmaceutics: X · 2026Review
- Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges.International journal of pharmaceutics: X · 2026Review
- Phage endolysin therapy: a modern antimicrobial strategy against highly drug-resistant superbugs.Archives of microbiology · 2026Review
- Detection to Disruption: A Comprehensive Review of Bacterial Biofilms and Therapeutic Advances.Antibiotics (Basel, Switzerland) · 2026Review
- Formulation-Dependent Antibacterial Performance: Design and Biomedical Applications.Gels (Basel, Switzerland) · 2026Review
- Enhancement of tobramycin and amikacin activities by co-encapsulation in liposomal-thymoquinone formulation: antibacterial, antibiofilm, and cytocompatibility study.Therapeutic delivery · 2026Article
- Methylene Blue-Loaded Liposomal Nanocarriers Enhance the Efficacy of Photodynamic Therapy againstACS infectious diseases · 2026Article
- Review
- Nano-enabled disruption of bacterial virulence and communication in plant pathosystems: emerging strategies for sustainable disease management.Frontiers in plant science · 2026Review
- Preparation and in vitro evaluation of photodynamic-responsive nanoliposome loaded PL-5.PloS one · 2026Article
- Liposome drug delivery strategies: state-of-the-art for combating bacterial biofilms.Frontiers in microbiology · 2026Review
- Hypoxia-responsive hybrid nanoparticles loaded with fingolimod and colistin against multidrug-resistantAsian journal of pharmaceutical sciences · 2025Article
- Evaluation of Combinatorial Efficacy of Nisin and Lactoferrin against Pseudomonas Aeruginosa Induced Experimental Pulmonary Infection Model.Current microbiology · 2025Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
All currently approved antibiotics are being met by some degree of resistance by the bacteria they target. Biofilm formation is one of the crucial enablers of bacterial resistance, making it an important bacterial process to target for overcoming antibiotic resistance. Accordingly, several drug delivery systems that target biofilm formation have been developed. One of these systems is based on lipid-based nanocarriers (liposomes), which have shown strong efficacy against biofilms of bacterial pathogens. Liposomes come in various types, namely conventional (charged or neutral), stimuli-responsive, deformable, targeted, and stealth. This paper reviews studies employing liposomal formulations against biofilms of medically salient gram-negative and gram-positive bacterial species reported recently. When it comes to gram-negative species, liposomal formulations of various types were reported to be efficacious against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.